Blockchain Registration Transaction Record

Oncotelic and Sapu Nano to Present Deciparticle Platform at BIO 2026

Oncotelic Therapeutics and Sapu Nano announce CEO Vuong Trieu will present the Deciparticle nanomedicine platform at BIO 2026, highlighting ultra-small formulations for water-insoluble drugs and AI integration.

This news matters because it signals a significant advancement in nanomedicine that could revolutionize the delivery of poorly soluble drugs, potentially improving treatment outcomes for cancer patients. The Deciparticle platform's ability to enable intravenous administration of water-insoluble therapeutics addresses a critical bottleneck in drug development, offering safer and more effective alternatives to current formulations that often rely on toxic solvents. For investors, the progress of Sapu006 and Sapu003 into Phase 1b trials indicates near-term catalysts, while the integration of AI through PDAOAI highlights a modern approach to accelerating drug development. This convergence of nanotech, AI, and oncology could reshape how difficult-to-formulate drugs are delivered, benefiting patients, clinicians, and shareholders alike.